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Dbl family GEFs (guanine nucleotide-exchange factors) for the
Rho GTPases almost invariably contain a PH (pleckstrin homo-
logy) domain adjacent to their DH (Dbl homology) domain. The
DH domain is responsible for GEF activity, and the PH domain
plays a regulatory role that remains poorly understood. We demon-
strated previously that Dbl family PH domains bind phospho-
inositides with low affinity and cannot function as independent
membrane targeting modules. In the present study, we show that
dimerization of a Dbs (Dbl’s big sister) DH/PH domain frag-
ment is sufficient to drive it to the plasma membrane through a
mechanism involving PH domain–phosphoinositide interactions.
Thus, the Dbs PH domain could play a significant role in mem-
brane targeting if it co-operates with other domains in the protein.
We also show that mutations that prevent phosphoinositide bind-
ing by the Dbs PH domain significantly impair cellular GEF
activity even in chimaeric proteins that are robustly membrane
targeted by farnesylation or by the PH domain of phospho-
lipase C-δ1. This finding argues that the Dbs PH domain plays a
regulatory role that is independent of its ability to aid membrane
targeting. Thus, we suggest that the PH domain plays dual roles,
contributing independently to membrane localization of Dbs (as
part of a multi-domain interaction) and allosteric regulation of the
DH domain.
Key words: Dbl’s big sister (Dbs), guanine nucleotide exchange
factor (GEF), membrane targeting, pleckstrin homology (PH)
domain, phosphoinositide, Rho.
INTRODUCTION
Dbl-related GEFs (guanine nucleotide-exchange factors) activate
Rho family small GTPases, which control many cellular processes
including organization of the actin cytoskeleton [1,2]. Dbl-related
GEFs contain a helical DH (Dbl homology) domain that is nearly
always followed by a PH (pleckstrin homology) domain [1].
The ∼200 amino acid DH domain harbours the guanine nucleo-
tide-exchange activity, selective for one or several Rho-family
GTPases [3,4]. The adjacent 120 amino acid PH domain
plays a modulatory role that appears to differ mechanistically
across this large family of proteins [5]. With more than
50 Dbl family proteins in the human proteome, and ∼250 PH
domains, approx. 20% of known human PH domains are linked
directly to a DH domain. Few of these PH domains are well
understood.
PH domains are best known for their ability to bind phospho-
inositides and to target their host proteins to cellular membranes
[6]. Although some PH domains bind strongly and specifically
to phosphoinositides, most do so only weakly and with little
specificity [7,8]. The binding properties of PH domains from
several Dbl family proteins have been analysed [9–11]. Each
binds phosphoinositides with an affinity [KD for PtdIns(4,5)P2
(phosphatidylinositol-4,5-bisphosphate) > 10 µM] that is thought
to be too low to drive membrane targeting independently. With the
exception of the Tiam-1 C-terminal PH domain, which shows spe-
cificity for PtdIns3P (phosphatidylinositol-3-phosphate) [9,12],
all DH-domain-associated PH domains are promiscuous in their
phosphoinositide binding. These findings argue that the PH do-
mains of Dbl family proteins do not simply target their host pro-
teins to cellular membranes. Indeed, PH domain mutations that
impair phosphoinositide binding did not affect subcellular local-
ization of Dbl family proteins in several reports [12–16], although
altered or reduced membrane localization was described in other
studies [15,17,18]. In all cases, regardless of whether subcellular
localization was altered, the same mutations significantly reduced
GEF activity of the Dbl protein in the same cells. Thus, phos-
phoinositide binding by the PH domain may play a role in GEF
activity distinct from (or in addition to) any role in driving mem-
brane association.
Structural studies have shown that the PH domain contributes
directly to the interaction of certain Dbl family GEFs with their
small GTPase targets [4,5,19–21]. Comparison of Dbs (Dbl’s big
sister) DH/PH structures with and without bound GTPase [22]
suggests a model in which phosphoinositide binding to the PH
domain at a membrane leads to a reorientation of the DH and
PH domains that maximizes their combined interaction with the
membrane-associated Rho-family GTPase. Focusing on Dbs, we
have been interested in understanding the relative contributions to
the GEF-activating effects of PH domain–phosphoinositide inter-
actions made by allosteric/conformational effects, and of simple
PH-domain-mediated membrane targeting.
Abbreviations used: BS3, bis(sulfosuccinimidyl) suberate; Dbs, Dbl’s big sister; DH, Dbl homology; DMEM, Dulbecco’s modified Eagle’s medium; EGFP,
enhanced green fluorescent protein; FBS, fetal bovine serum; FKBP, FK506-binding protein; GEF, guanine nucleotide-exchange factor; GST, glutathione
S-transferase; H-Ras, Harvey-Ras; PAK1, p21-activated protein kinase; PBD, p21-binding domain; PH, pleckstrin homology; PLC, phospholipase-C;
PtdIns3P, phosphatidylinositol-3-phosphate; PtdIns(4,5)P2, phosphatidylinositol-4,5-bisphosphate; Ras-GRF, Ras guanine-nucleotide releasing factor;
RBD, Rho-binding domain; SH3, Src homology 3; SPR, surface plasmon resonance; TTBS, Tris-buffered saline containing 0.1% Triton X-100.
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Dbs was originally identified in a retroviral murine cDNA
library screen for genes that transform NIH 3T3 cells [23], and
was called Dbs because of its similarity to Dbl. The 1149 amino
acid murine Dbs gene product contains a SEC14 domain (residues
82–219), SPEC (spectrin repeat) domains (residues 352–539), a
DH domain (residues 623–819), a single PH domain (residues
820–967) and an SH3 (Src homology 3) domain (residues 1060–
1108). The DH domain of Dbs activates RhoA and Cdc42 in
cellular and in vitro studies [13,15,19,24]. PH domain deletion
eliminates the ability of Dbs to transform cells, but addition of
the H-Ras (Harvey-Ras) far (farresylation) sequence to the DH
domain partially rescues transforming activity [24]. Thus, simple
membrane recruitment may play some role in the contribution of
the PH domain to Dbs function. We find that the GEF activity
of the Dbs DH/PH fragment can be enhanced by targeting it to
the plasma membrane by dimerization (to increase PH domain
avidity) or by fusion to known membrane-targeting sequences.
However, even when Dbs is membrane-targeted, mutations intro-
duced into the PH domain that reduce phosphoinositide bind-
ing impair GEF activity. Our results therefore suggest that, while
the PH domain may participate in driving membrane localiz-
ation of Dbs (as one of several co-operating domains), this may
be secondary to its role in phosphoinositide-regulated conform-
ational changes that enhance GEF activity.
EXPERIMENTAL
Plasmid constructs and mutagenesis
DNA encoding the murine Dbs DH/PH region (amino acids
623–967) was amplified by PCR and subcloned in between the
BamHI and EcoRI sites of pGEX-2TK (Amersham Pharmacia
Biotech). The resulting GST (glutathione S-transferase)–DH/PH
fusion protein has a PKA (protein kinase A) phosphorylation site
between the GST moiety and the DH/PH fragment. To generate
a dimerizable DH/PH fragment [fused to EGFP (enhanced green
fluorescent protein)], the FKBPF36V (FK506-binding protein) se-
quence was fused to the Dbs DH/PH coding sequence, and the
resulting fusion (Figure 1A) was subcloned between the BglII
and EcoRI sites of pEGFP-C1 (Clontech, Palo Alto, CA, U.S.A.).
DNA encoding the rat PLC-δ1 (phospholipase C-δ1) PH domain
(amino acids 11–127) was subcloned between the BglII and
EcoRI sites of pEGFP-C1 to generate an EGFP–PLC-δ1-PH do-
main fusion, and was also fused to the C-terminus of pEGFP–
DH/PH-FKBPF36V to produce the fusion protein EGFP–DH/PH-
FKBPF36V–PLC-δ1-PH. A fusion protein with the PLC-δ1 PH
domain linked directly to the C-terminus of an EGFP–Dbs DH
fusion protein (containing amino acids 623–824 from Dbs) was
also generated. This is EGFP–Dbs DH–PLC-δ1-PH. As an alter-
native mode of membrane targeting, the coding sequence of H-
Ras1 (amino acids 170–189), corresponding to its far signal, was
fused to the C-terminus of pEGFP–DH/PH (using the EcoRI site)
to generate the fusion protein EGFP–DH/PH–far.
PH domain mutations were made in the GST–DH/PH, EGFP–
DH/PH-FKBPF36V, EGFP–DH/PH-FKBPF36V–PLC-δ1-PH and
EGFP–DH/PH–far proteins. All mutations were generated using
the QuikChangeTM Site-Directed Mutagenesis Kit (Stratagene).
Amino-acid replacements made in the PH domain β1/β2 loop
(PH*; K849Q, K851Q, R855Q and K857Q) and β2 strand
(R861Q) are depicted in Figure 2(A). Constructs expressing the
PBD (p21-binding domain; amino acids 67–150) of human PAK1
(p21-activated kinase-1) [25] and the RBD (Rho-binding domain;
amino acids 7–89) of murine Rhotekin [26] were provided kindly
by Dr Channing Der (Lineberger Comprehensive Cancer Center,
University of North Carolina, Chapel Hill, NC, U.S.A.) and
Figure 1 The DH/PH fragment of Dbs can be driven to the plasma membrane
by dimerization
(A) FKBPF36V was fused to the C-terminus of an EGFP–Dbs DH/PH fragment to give the
EGFP–DH/PH–FKBPF36V fusion protein schematized here. Amino acid numbers correspond-
ing to domain boundaries are given. HeLa cells transiently transfected with the EGFP–DH/
PH–FKBPF36V construct (containing the wild-type Dbs PH domain) were either untreated (B) or
treated (C) with the AP20187 dimerizer at a final concentration of 200 nM (see Experimental
section), and live cells were visualized by fluorescence microscopy after the indicated times.
(D) AP20187 addition promotes dimerization of the EGFP–DH/PH–FKBPF36V fusion protein
as assessed by cross-linking with BS3 (see Experimental section). Whole-cell lysates were
subjected to treatment with BS3, and analysed by SDS/PAGE and immunoblotting with an
anti-GFP antibody.
Dr Xiang-Dong Ren (Department of Dermatology, Stony Brook
University, Stony Brook, NY, U.S.A.) respectively.
Overlay analysis of phosphoinositide binding
The Dbs GST–DH/PH and GST–DH/PH* fusion proteins were
expressed in Escherichia coli, purified, labelled with 32[P]Pi, and
used in lipid-overlay experiments exactly as described previously
[7,12], with serial 2-fold dilutions of lipids [starting with 2 mg/ml
in 1:1 (v/v) chloroform/methanol containing 0.1% HCl] spotted
on to a nitrocellulose membrane.
SPR (surface plasmon resonance)
SPR studies of phosphoinositide binding were performed exactly
as described previously [8], using a Biacore X.
Activated Cdc42- and RhoA-pulldown assays
Pull-down assays to assess cellular levels of activated Cdc42 and
RhoA were performed as described previously [25,26]. HeLa cells
were seeded in DMEM (Dulbecco’s modified Eagle’s medium)
and 10% (v/v) FBS (fetal bovine serum) at 8 × 106 cells per 10 cm
diameter plate. After 15 h, cells were transfected with 20 µg
of the relevant DNA using LipofectamineTM 2000 (Invitrogen).
After 4 h, cells were washed twice in PBS and resuspended in
DMEM with 0.1% FBS for a further 16 h. Cells were then lysed
in ice-cold lysis buffer [25 mM Hepes, pH 7.5, 150 mM NaCl,
1% (v/v) Nonidet P40, 0.25% sodium deoxycholate, 10% (w/v)
c© 2006 Biochemical Society
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Figure 2 Mutations in the PH domain of Dbs abolish its weak PtdIns(4,5)P2 binding
(A) The sequence from strand β1 to β3 of the Dbs PH domain is shown, corresponding to the region of PH domains known to interact with phosphoinositides [32]. Mutations (to glutamine)
were introduced into the β2 strand (R861Q) or at four basic residues (K849, K851, R855, and K857) in the β1/β2 loop (PH*) of the Dbs PH domain as indicated by the grey boxed Qs.
(B) 32P-Labelled GST–DH/PH (10 µg) was used to probe nitrocellulose filters spotted with serial 2-fold dilutions of PtdIns3P, PtdIns(3,5)P2, PtdIns(3,4,5)P3, PtdIns(4,5)P2 and phosphatidylserine
(PtdSer) as marked (beginning at 2 mg/ml). (C) GST–DH/PH and GST–DH/PH* proteins were assessed for binding to PtdIns(4,5)P2 using SPR as described [8]. GST–DH/PH or GST–DH/PH*
at a series of concentrations were flowed over a Biacore sensor chip containing 3 % (mol/mol) PtdIns(4,5)P2 in dioleoylphosphatidylcholine. Steady-state binding signals are plotted against
protein concentration, with the best-fit to a simple 1:1 binding curve superimposed. The K D (app) value for binding of (dimeric) GST–DH/PH (wild-type) was approx. 7.5 µM. The inset curve
demonstrates saturation of PtdIns(4,5)P2 binding by GST–DH/PH. GST–DH/PH* gave no significant binding signal at any concentration tested. Curves are representative of at least three independent
experiments. (D) Introduction of PH* mutations (which prevent phosphoinositide binding as shown in B and C) abolished the ability of the EGFP–DH/PH*–FKBPF36V to translocate to the plasma
membrane upon addition of AP20187. Details are as described for Figures 1(B) and 1(C). BS3 cross-linking experiments were performed as in Figure 1(D) and show that AP20187 induces robust
EGFP–DH/PH*–FKBPF36V dimerization.
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glycerol, 10 mM MgCl2 and 1 mM PMSF] and spun at 16000 g in
a microcentrifuge at 4 ◦C for 4 min. Supernatant (lysate) was re-
tained and the total protein concentration in each sample was
measured using the bicinchoninic acid protein assay (Pierce,
Rockford, IL, U.S.A.). Total protein (70 µg) from the lysate was
saved for Western blotting controls (to assess total Cdc42, RhoA,
and Dbs expression levels). For activated Cdc42-pulldown assays,
600 µg of total protein was incubated with 30 µg of PAK1 PBD
bound to glutathione–agarose (Sigma) for 1 h at 4 ◦C. Agarose
beads were washed twice in 4 ◦C lysis buffer, resuspended in
SDS/PAGE sample buffer [62.7 mM Tris/HCl, pH 6.8, 2% (w/v)
SDS, 10% (w/v) glycerol and 0.01 % Bromophenol Blue], and
boiled for 3 min prior to analysis by immunoblotting with mouse
anti-Cdc42 (610929 clone 44; BD Transduction Laboratories,
Lexington, KY, U.S.A.) at 1:300 dilution in TTBS (Tris-buffered
saline containing 0.1% Triton X-100) with 5% (w/v) dried milk
powder (for PAK1 PBD pull-down or whole-cell lysate samples).
For activated RhoA-pulldown assays, 1 mg of total protein
was incubated with 30 µg of GST–RBD bound to glutathione–
agarose (Sigma) for 1 h at 4 ◦C. Agarose beads were washed
twice in cold lysis buffer (without Nonidet P40), resuspended
in SDS/PAGE sample buffer, and boiled for 3 min prior to
analysis by immunoblotting. Mouse anti-RhoA (sc-179; Santa
Cruz Laboratories; Santa Cruz, CA, U.S.A.) at 1:250 dilution
in TTBS containing 5% (w/v) dried milk powder was used for
Western blotting of RBD pull-down or whole-cell lysate samples.
Mouse anti-GFP (B34; Covance Research Products, Berkeley,
CA, U.S.A.) was used at 1:10000 dilution in TTBS containing
5% (w/v) dried milk powder for Western blots of whole-
cell lysate samples to assess levels of GFP fusion protein ex-
pression.
In vitro nucleotide-exchange assays
Nucleotide-exchange assays were performed exactly as described
previously [19], monitoring incorporation of N-methylanthra-
niloyl-GTP (Molecular Probes) into Cdc42 or RhoA expressed
and purified from E. coli. Exchange assay reaction mixtures
contained 20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl2,
1 mM dithiothreitol and 100 µM N-methylanthraniloyl-GTP, plus
2 µM GTPase (Cdc42 or RhoA).
Fluorescence microscopy
HeLa cells were plated at 3.75 × 105 cells per 13-mm-diameter
dish and transfected after 12 h with 2 µg of the relevant pEGFP-
C1 derivative using LipofectamineTM 2000 (Invitrogen). After 4 h,
cells were washed twice in PBS and resuspended in DMEM with
0.1% FBS for a further 16 h. Living cells were then visualized
using a Leica DM-IRB inverted fluorescence microscope and
0.1 µm z-sections were collected and processed using OpenLab
deconvolution software.
For in vivo dimerization experiments, cells in fresh DMEM
containing 10% (v/v) FBS in a 13-mm-diameter dish were
placed in a 37 ◦C incubation block attached to a Leica DM-IRB
inverted fluorescence microscope 14 h after transfection, and the
AP20187 dimerizer (ARIAD Pharmaceuticals Inc., Cambridge,
MA, U.S.A.) was added to a final concentration of 200 nM in
the medium (from a 100 µM stock solution in ethanol). Cells
were monitored for changes in localization of the EGFP-tagged
FKBPF36V fusion proteins by fluorescence microscopy beginning
1 min after the addition of AP20187 and every 15 min thereafter.
As a control, HeLa cells transfected with parental pEGFP-C1
were treated with dimerizer as described above and observed for
changes in localization of EGFP.
Chemical cross-linking studies
HeLa cell lysates were treated with the covalent cross-linker
BS3 [bis(sulfosuccinimidyl) suberate]. The cells were incubated
for 15 h after transfection with 20 µg of the relevant expression
construct, and then the AP20187 dimerizer was added to a final
concentration of 200 nM. After a further 3 h, cells were washed
in cold PBS containing dimerizer, and lysed in 20 mM phosphate
buffer, pH 7.5, containing 150 mM NaCl, 1% (v/v) Triton X-100,
10 µg/ml aprotinin, 0.5 mM PMSF and dimerizer. The lysate was
centrifuged at 16000 g for 10 min and BS3 was added to the
supernatant (from a 10 mM stock in 20 mM phosphate buffer,
pH 7.5) to a final concentration of 0.25 mM for 30 min at room
temperature (22 ◦C). The cross-linking reaction was quenched
with 20 mM glycine, pH 9.5, for 15 min, and the lysate was
analysed by SDS/PAGE and immunoblotting with an anti-GFP
antibody as described above (see Figure 1D).
RESULTS
In agreement with the argument that the PH domain of Dbs
does not function as a simple independent membrane-targeting
module [5], we found that an EGFP fusion protein containing
the isolated Dbs DH/PH fragment (residues 623–967) is entirely
cytoplasmic, with no evidence for defined subcellular localization
(Figure 1B). However, this does not rule out the possibility that the
Dbs PH domain nonetheless contributes to membrane association
in a functionally important way, perhaps by co-operating with
other membrane-targeting domains within the same protein (or
in an oligomer). For example, the PH domain could co-operate
with the N-terminal Sec14 domain in Dbs, also reported to bind
phosphoinositides [27], to drive the protein to phosphoinositide-
rich areas of the plasma membrane. Similarly, if Dbs forms oligo-
mers, as reported for Dbl, Ras-GRF 1/2 (Ras guanine-nucleotide-
releasing factor 1/2) and Cool-2 [28–30], multiple PH domains
within the same oligomer could co-operate with one another
to drive high-avidity (multivalent) membrane recruitment, as
demonstrated previously for the PH domain of dynamin
[31,32].
Dimerization can drive translocation of the Dbs DH/PH fragment to
the plasma membrane
To determine whether the Dbs PH domain can promote membrane
association as part of a multi-domain interaction, we generated
an artificial chemically-inducible dimer of the DH/PH fragment
and investigated its subcellular localization. We appended an
F36V mutant of FK506 binding protein-12 to the C-terminus of
an EGFP–DH/PH fusion to give the EGFP–DH/PH–FKBPF36V
protein in Figure 1(A). A cell-permeant dimeric analogue of
FK506 (AP20187) binds bivalently to two FKBP molecules (with
a KD ≈ 1 nM), and induces efficient dimerization of this fusion
protein [33]. Corvera et al. [34] have used this approach to in-
crease the avidity of FYVE domain interactions with PtdIns3P-
containing endosomal membranes.
The EGFP–DH/PH–FKBPF36V fusion protein was completely
diffuse and cytoplasmic when transiently expressed in HeLa
cells without added dimerizer (Figure 1B). However, when
AP20187 dimerizer was added to a final concentration of 200 nM
(see Experimental section), plasma membrane association was
discerned within 1 min in approx. 30% of transfected cells (Fig-
ure 1C), and this intensified significantly over the next 45 min.
AP20187 treatment had no influence on the distribution of EGFP
in HeLa cells expressing EGFP alone (results not shown). To
confirm that 200 nM AP20187 induces efficient dimerization
c© 2006 Biochemical Society
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Figure 3 PH domain mutations do not impair solubility or in vitro GEF activity of the Dbs DH/PH fragment
(A) A Coomassie Blue-stained SDS/PAGE gel of E. coli-expressed wild-type (WT), R861Q and PH* forms of GST–DH/PH after one-step purification with glutathione–agarose beads is shown.
Expression levels, solubility and stability appeared identical for the three proteins. In vitro GTP/GDP exchange on Cdc42 (B) and RhoA (C) was measured for wild-type (WT) and mutated GST–DH/PH
proteins as described in the Experimental section. The data were fitted as single exponential decays, giving k obs for Cdc42 of 0.15 × 10−3 s−1 (no GEF), 4.29 × 10−3 s−1 (wild-type), 3.72 × 10−3
s−1 (R861Q) and 6.02 × 10−3 s−1 (PH*). Rates for RhoA were 0.31 × 10−3 s−1 (no GEF), 2.25 × 10−3 s−1 (wild type), 1.97 × 10−3 s−1 (R861Q) and 3.99 × 10−3 s−1 (PH*). Each experiment
was performed twice with identical results.
of the EGFP–DH/PH–FKBPF36V fusion protein, we incubated
lysates from AP20187-treated cells with the bifunctional cross-
linking agent BS3. An anti-GFP Western blot (Figure 1D) showed
that EGFP–DH/PH–FKBP dimers were only cross-linked follow-
ing treatment of cells with AP20187. Sedimentation equilibrium
analytical ultracentrifugation studies (results not shown) con-
firmed that an E. coli expressed Dbs DH/PH fragment was entirely
monomeric at concentrations up to 10 µM. Thus, dimerization of
the Dbs DH/PH fragment is sufficient to drive it to the plasma
membrane of HeLa cells.
Membrane targeting of the dimerized Dbs DH/PH fragment is
PH-domain-mediated
To determine whether the membrane targeting seen in Figure 1(C)
required PH domain–phosphoinositide interactions, we made
mutations to disrupt PtdIns(4,5)P2 binding by the Dbs PH domain
(Figure 2A). Arg861 in the β2 strand of the Dbs PH domain [19]
corresponds to a critical and reasonably well-conserved residue
in the lipid-binding site, at which mutations usually abolish
PH domain phosphoinositide binding [32]. Rossman et al. [13]
showed previously that the R861Q mutation impairs phospho-
inositide binding significantly. In our lipid-overlay studies using
an E. coli-produced GST–DH/PH fusion protein, we found that
significant residual phosphoinositide binding remained in the
R861Q mutant (Figure 2B). We therefore replaced four basic
residues in the β1/β2 phosphoinositide-binding loop (K849,
K851, R855 and K857) with glutamine to generate the PH*
variant. GST–DH/PH* showed no detectable phosphoinositide
binding in lipid overlay studies (Figure 2B), and gave no signifi-
cant PtdIns(4,5)P2-binding signal when analysed in SPR studies
(Figure 2C), even when injected at 100 µM.
As shown in Figure 2(D), the EGFP–DH/PH*–FKBPF36V fusion
protein does not become membrane associated upon addition of
c© 2006 Biochemical Society
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Figure 4 Membrane targeting of the Dbs DH/PH fragment
(A) Schematic representation of the chimaeric constructs employed for membrane targeting of DH/PH and DH/PH*. To target the Dbs DH/PH fragment with PLC-δ1-PH, the PLC-δ1 PH domain was
fused to the C-terminus of the EGFP–DH/PH–FKBPF36V chimaera shown in Figure 1(A), using the FKBP moiety as a spacer between the two PH domains. For targeting the DH/PH fragment by
farnesylation (far), the farnesylation sequence of H-Ras was fused directly to the C-terminus of the EGFP–DH/PH fusion. To analyse the isolated DH domain, PLC-δ1-PH was fused directly to its
C-terminus. Constructs including the Dbs PH domain were made with both the wild-type and PH* versions of the PH domain. The nomenclature used in the text for each construct is noted above
its scheme. (B) Membrane localization of each EGFP chimaera was assessed by fluorescence microscopy of transiently-transfected live HeLa cells. No significant plasma membrane localization
is seen for EGFP, or EGFP–DH/PH (wild-type or PH*). All fusion proteins containing PLC-δ1-PH or the far signal were robustly targeted to the plasma membrane. Structures resembling filopodia
were seen in more than 60 % of cells (n = 150) exhibiting membrane localization of a DH-domain-containing fragment (DH/PH–PLC δ1 PH, DH/PH*–PLC δ1 PH, DH/PH–far, DH/PH*–far and
DH–PLC δ1 PH).
the AP20187 dimerizer. This finding suggests that dimerizer-in-
duced membrane translocation of the wild-type EGFP–DH/PH–
FKBPF36V fusion is driven primarily by its PH domain, and
requires both the ability of the PH domain to bind phosphoino-
sitides and its dimerization. It therefore seems reasonable to
argue that the Dbs PH domain could contribute to membrane
targeting of full-length Dbs in a functionally important way by
co-operating with other domains in Dbs or with other PH domains
in a Dbs oligomer. When fused to GST, which dimerizes with high
affinity [35], the Dbs DH/PH fragment binds to lipid vesicles
containing 3% (mol/mol) PtdIns(4,5)P2 with a KD (app) of
7.5 µM as assessed by SPR studies (Figure 2C). This is in the
range where membrane targeting should be evident in cellular
studies [32], particularly if DH domain interactions with Cdc42
or RhoA can also contribute. By contrast, we could not detect
PtdIns(4,5)P2 binding by the monomeric DH/PH fragment in SPR
studies at the concentrations tested here (results not shown). We
reported previously [31] a similar observation for the dynamin PH
domain. In that case, the phosphoinositide head-group binding by
a monomeric PH domain had a KD value in the 1–2 mM range
[36,37], and dimerization mediated by GST brought the KD for
PtdIns(4,5)P2 in membranes to approx. 20 µM [31]. Thus, the
phosphoinositide-binding characteristics of the Dbs and dynamin
PH domains are rather similar. In both cases, mutations that impair
the very low-affinity phosphoinositide binding also impair cellular
function of the respective protein [13,15,38–40]. Dbs PH there-
fore represents another example in which low-affinity phospho-
inositide binding by a PH domain appears to be functionally
relevant, possibly through its involvement in multivalent inter-
aticactions with membranes [32].
PH domain mutations do not affect solubility or intrinsic GEF
activity of DH/PH fragments
The mutations detailed in Figure 2(A) do not appear to cause
misfolding, insolubility or instability of the expressed polypep-
tides. Each mutant was expressed well (and solubly) in E. coli at
37 ◦C with similar yields, as shown in Figure 3(A). In addition,
to confirm that the PH domain mutations do not affect intrinsic
GEF activity, we assayed the Cdc42- and RhoA-exchange activity
of each GST–DH/PH fusion protein in vitro, using fluorescence
spectroscopy to monitor N-methylanthraniloyl-GTP binding (see
Experimental section). As shown in Figures 3(B) and 3(C), the in-
trinsic ability of the Dbs DH/PH fragment to promote nucleotide
exchange on soluble GTPases was not impaired by PH domain
mutations. Since the observed in vitro GEF activity of the Dbs
DH/PH fragment requires that the PH domain is correctly folded
[19], these observations argue that the PH* mutations reduce
phosphoinositide binding without impairing overall structure.
Membrane targeting of the Dbs DH/PH fragment promotes Rho
GTPase activation
In the dimerizer studies described in Figure 1(C), we noticed
AP20187-dependent formation of membrane protrusions that
resemble filopodia in cells with membrane-translocated EGFP–
DH/PH–FKBPF36V. This might reflect Cdc42 activation by the
membrane-translocated DH/PH fragment, which in turn leads
to filopodia formation [2,41]. We were not able to detect
Cdc42 or RhoA activation reproducibly using biochemical assays
in dimerizer-treated cells expressing EGFP–DH/PH–FKBPF36V.
Reasoning that this might reflect relatively weak membrane
association (and GEF activity) of dimerized EGFP–DH/PH–
FKBPF36V, we generated alternative constructs in which more ro-
bust plasma membrane-targeting domains were fused to a mono-
meric Dbs DH/PH fragment. In one set of constructs, we fused
the PLC-δ1-PH domain to the C-terminus of EGFP–DH/PH–
FKBPF36V (to give DH/PH–PLCδ1PH in Figure 4A), maintaining
the FKBPF36V moiety as a ‘spacer’ between the Dbs DH/PH
fragment and the PLC-δ1-PH domain. PLC-δ1-PH binds with
high affinity to PtdIns(4,5)P2 [32], and is targeted robustly to the
plasma membrane of mammalian cells [42]. In another approach,
to drive PtdIns(4,5)P2-independent plasma membrane targeting,
we fused the H-Ras far sequence to the C-terminus of the
Dbs DH/PH fragment (to give DH/PH–far in Figure 4A), as
described for plasma membrane targeting of other proteins
[43,44]. We also generated an EGFP fusion protein with the
PLC-δ1 PH domain linked directly to the C-terminus of the Dbs
c© 2006 Biochemical Society
Role of the PH domain in Dbs targeting and regulation 569
Figure 5 RhoA activation by membrane-targeted Dbs DH/PH
(A) Representative immunoblots for RhoA activation experiments. HeLa cells were transfected
with the indicated construct (see Figure 4A), and the active pool of (GTP-bound) RhoA was
specifically isolated from serum-starved cells by affinity chromatography using GST–Rhotekin
RBD as described in the Experimental section. The top and middle panels were immunoblotted
with an antibody to RhoA, and represent (top) RhoA protein precipitated with GST–Rhotekin RBD
(GTP-bound, active) and (middle) whole-cell lysate (total RhoA). The bottom panel represents
whole-cell lysate immunoblotted with an antibody against GFP for comparison of expression
levels of the different chimaeric Dbs DH/PH. (B) Immunoblots from at least three independent
experiments were quantified using Kodak ImageStation software. The normalized intensity of
each band was evaluated as a percentage of the maximum RhoA activation in that experiment,
and results are presented as means +− S.D.
DH domain (DH–PLCδ PH in Figure 4A), effectively replacing
the Dbs PH domain with PLC-δ1-PH. For the remainder of the
manuscript, all chimaeric proteins discussed are fused to EGFP,
and will be referred to according to the convention shown
in Figure 4A (with PH* denoting the presence of the PH*
mutations shown in Figure 2A). Fluorescence microscopy studies
(Figure 4B) demonstrated that fusing PLC-δ1-PH or the H-Ras
plasma-membrane-targeting signal promotes significant plasma
membrane localization of the EGFP–DH/PH fusions (similar to
that seen with EGFP–PLC-δ1-PH), regardless of the presence
Figure 6 Cdc42 activation by membrane-targeted Dbs DH/PH
(A) Representative immunoblots for Cdc42 activation experiments. Experiments were performed
as for Figure 5(A), but using GST–PAK PBD to specifically isolate activated Cdc42. Top and
middle panels were immunoblotted with an antibody to Cdc42, and represent activated (top)
and total (middle) Cdc42 respectively. The bottom panel represents whole-cell lysate
immunoblotted with an antibody against GFP for assessing Dbs fragment expression levels.
(B) Quantification of Cdc42 activation experiment, as described in the legend to Figure 5(B).
of PH* mutations. By contrast, the chimaeric DH/PH and
DH/PH* showed no evidence at all of concentration at the plasma
membrane, and were indistinguishable from EGFP alone.
We assessed levels of activation of endogenous RhoA and
Cdc42 in HeLa cells transiently expressing the membrane-
targeted Dbs chimaeric DH/PH shown in Figure 4. We used the
RBD of Rhotekin to selectively precipitate activated RhoA from
transfected cells [26]. To determine levels of Cdc42 activation,
we used PAK1 PBD to selectively precipitate GTP-bound Cdc42
[25]. Parallel immunoblots of GTP-bound and total RhoA or
Cdc42 then allowed an estimation of the relative proportion of
the small GTPase that had been activated. Although expression
of the chimaeric DH/PH enhanced RhoA (Figure 5) and Cdc42
(Figure 6) activation to some extent in HeLa cells, membrane
targeting of the DH/PH fragment by fusion to PLC-δ1-PH (in
DH/PH–PLCδ PH) or far (in DH/PH–far) led to a significant
further increase (compare lanes 5 and 7 with lanes 3 in Fig-
ures 5 and 6). Thus, membrane targeting appears to be sufficient
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Figure 7 Schematic model for the role of the Dbs PH domain in regulating GEF activity
Membrane recruitment of Dbs is promoted by the co-operation of multiple domains, including the Sec14 domain [27], possibly the SH3 domain, plus PH domain–phosphoinositide interactions,
PH domain–GTPase (Cdc42 or RhoA) interactions, and DH domain–GTPase (Cdc42 or RhoA) interactions. At the plasma membrane, optimal binding to the GTPase target requires ligation of
the PH domain by PtdIns(4,5)P2 in order to relieve possible steric hindrance to DH domain interactions and maximize interactions between the GTPase and the PH domain. In the case of Cdc42,
relief of inhibition may play a more important role, as discussed in the text. Our results suggest that the PH domain interactions may be more important in the case of RhoA, as indicated in the Figure.
D, GDP bound to Cdc42 or RhoA; T; GTP-bound state.
to promote GEF activity of the Dbs DH/PH fragment in a
cellular context, consistent with the appearance of filopodia in
cells with a membrane-targeted dimeric DH/PH fragment. Expres-
sion of each membrane-targeted DH/PH-containing chimaera in
Figure 4(B) also led to the appearance of structures resembling
filopodia that were absent in cells expressing EGFP or an EGFP–
PLC-δ1-PH fusion protein.
PH domain mutations impair in vivo GEF activity even in the
context of membrane-targeted Dbs fragments
If the primary role of phosphoinositide binding by the Dbs PH
domain is to promote membrane targeting, wild-type and PH*
mutants of otherwise membrane-targeted Dbs DH/PH fragments
should be equivalent in their cellular GEF activity. Contrary to this
notion, however, PH*-mutated Dbs DH/PH fragments showed
significantly reduced apparent RhoA-GEF activity even when
membrane-targeted by PLC-δ1-PH (Figure 5; compare lane 5
with lane 6) or farnesylation (Figure 5; compare lane 7 with
lane 8). The PH* mutations do not appear to alter membrane
targeting of DH/PH–PLC-δ1-PH or DH/PH–far (Figure 4B), yet,
in an already membrane-targeted context, the PH* mutations
significantly reduce GEF activity. This observation suggests a
specific role for PH domain–phosphoinositide interactions in
regulating Dbs activity at the membrane. Similar observations
were also made for Cdc42 activation (Figure 6), although the
effect of the PH* mutation on GEF activity of the chimaeric
DH/PH–far was less clear. The PH* mutation also reduced RhoA
and Cdc42 activation by the chimaeric DH/PH, which may reflect
a reduction in its low level of membrane targeting.
Finally, by analysing cells expressing DH–PLCδPH, we
tested the cellular GEF activity of the membrane-targeted DH
domain alone (fused to PLC-δ1-PH without including the Dbs
PH domain). As seen in Figures 5 and 6, lanes 9, DH–
PLC-δ1-PH expression led to robust Cdc42 activation (Figure 6),
but had only a small effect on RhoA activation (Figure 5). Inter-
estingly, comparing lane 6 with lane 9 in Figure 6 suggests that
a phosphoinositide-binding-defective PH domain may actually
have a negative influence on the ability of the DH domain to
activate Cdc42 (but not RhoA).
DISCUSSION
We conclude from these findings that the Dbs PH domain has the
capacity to modify subcellular localization of Dbs, but only as
one component of a multidomain interaction. If full-length Dbs
forms oligomers, as reported for Dbl, Ras-GRF and Cool-2 [28–
30], multiple copies of the Dbs PH domain could co-operate in
targeting these oligomers to the plasma membrane. More likely,
the Dbs PH domain might contribute to membrane association
of the whole protein through co-operation with one or more
other membrane-targeting domains within Dbs. In addition to
an SH3 domain at its C-terminus that could bind to proline-
rich regions of a membrane-localized protein, Dbs contains a
SEC14 domain at the N-terminus. The SEC14 domain, first
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identified in yeast in a phosphatidylinositol transfer protein [45],
has been shown to bind phospholipids in vitro and in vivo
[45,46]. The SEC14 domains of Dbl, Ost (the rat orthologue of
Dbs) and Dbs were recently reported to bind to phosphoinositides
and to contribute significantly to the subcellular localization of
these proteins [27,47]. In either case, the fact that only two PH
domains are required for membrane targeting (i.e. a DH/PH dimer
is significantly membrane-associated) argues that the Dbs PH
domain can contribute a significant amount of binding energy to
membrane association of the whole protein.
To investigate whether PtdIns(4,5)P2 binding by the Dbs
DH/PH fragment plays a role independent of its ability to promote
membrane targeting, we analysed Cdc42 and RhoA activation in
HeLa cells by mutants defective in PtdIns(4,5)P2 binding that
were robustly membrane targeted by PLC-δ1-PH or a farnesyl
group. Activation of both small GTPases was reduced as a result
of these mutations, even when made in the context of a strongly
membrane-targeted DH/PH-containing protein. This observation
supports the hypothesis that phosphoinositide binding by the
Dbs PH domain plays an important role beyond its contributions
to membrane targeting, in agreement with previous arguments
[13,15]. Interestingly, when the isolated DH domain from Dbs
was plasma membrane targeted by direct fusion to PLC-δ1-PH,
RhoA activation was minimal (Figure 5), but Cdc42 activation
was significant (Figure 6). Crystallographic studies show that
Cdc42 and RhoA interact directly with both the DH and PH
domains of Dbs [4,19]. The fact that the PH domain appears
more important for RhoA than for Cdc42 activation may indicate
that PH domain contacts play a greater role in assisting RhoA
exchange than Cdc42 exchange, perhaps because of stronger
PH domain–RhoA interactions or weaker DH domain–RhoA
interactions. It is therefore interesting that the crystal structure
of the Dbs DH/PH fragment bound to RhoA shows at least one
additional hydrogen bond between the PH domain β3/β4 loop and
the RhoA switch 2 region (i.e. between Tyr883 of the PH domain
and Arg68 of RhoA) that is not present in the Cdc42 complex [4].
Crystal structures are now available for the Dbs DH/PH
fragment alone [22], in complex with Cdc42 [19] and in complex
with RhoA [4]. Analysis of the GTPase-free structure indicates
that the spatial relationship between the PH and DH domains
is not fixed, and suggests that phosphoinositide binding to the
PH domain may restrict conformational heterogeneity so that
the relationship between DH and PH domains is ideal for optimal
productive interactions of both domains with Cdc42 and RhoA
[22]. In the context of this model, our results suggest (Figure 7)
that RhoA activation requires its interaction with both the DH
and PH domains, which is optimized by PtdIns(4,5)P2 binding.
Association with the DH domain alone is not sufficient. For Cdc42
activation, DH domain interactions may dominate (and may be
sufficient on their own). PtdIns(4,5)P2 binding may relieve a
negative influence of the PH domain on Cdc42–DH domain inter-
actions, in addition to optimizing the observed Cdc42–PH domain
interactions.
In the Dbl family of proteins, which accounts for a signifi-
cant fraction of all PH-domain-containing proteins, the phospho-
inositide-binding properties and subcellular localization of iso-
lated PH domains argues that they contribute to, but do not
dominate or drive, membrane targeting. Once at the membrane
surface, however, PH domain binding to phosphoinositides ap-
pears to stabilize a DH/PH conformation that is optimal for Rho-
family GTPase activation, presumably restricting activation of
these GTPases to phosphoinositide-containing membranes.
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